INK 128 (MLN0128) 化学構造
分子量: 309.33

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。
ターゲット mTOR
IC50 1 nM [1]
In vitro試験 INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases. [1] As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
PANC-1  NY\Ofo9pS2WubDDWbYFjcWyrdImgRZN{[Xl? MYqxMVExOCCwTR?= NEDX[|Q4OiCq MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NH;TUGszPDl5MUW0OC=>
PANC-1  Ml3vR4VtdCCYaXHibYxqfHliQYPzZZk> NV3KeW5bPTBibl2= NFizXmgzPC17NjDo M{DIc4lvcGmkaYTzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? M2PTclI1QTdzNUS0
MIA PaCa-2 NVzJOFhES2WubDDWbYFjcWyrdImgRZN{[Xl? MljBNU0yODBibl2= MY[3NkBp NVizVVlGcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NXnLOJhPOjR7N{G1OFQ>
PANC-1  MnjkRZBweHSxc3nzJGF{e2G7 MXKxNE0yODBibl2= MYG3NkBp NULzb5RpcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NV73boQyOjR7N{G1OFQ>
PANC-1  NXrhSXprTnWwY4Tpc44hSXO|YYm= M4TJblExNzVyIH7N M2Dk[lI1KGh? MX\kdoFu[XSrY3HscJkhcW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKDSHLVLQNU1UPktzIDjtWG9TSzFiYXP0bZZifGmxbjDpcoRq[2G2b4LzLUBidmRiQXv0JIF1KFOncjC0O|MhMHSqZTDtWG9TSzJiYXP0bZZifGmxbjDpcoRq[2G2b4Kp NHL4bm4zPDl5MUW0OC=>
PANC-1  NW\rN2Z{TnWwY4Tpc44hSXO|YYm= NFXCcZI2OCCwTR?= NXvxWXZFPDhiaB?= M3S1PYRqe3K3cITzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25? MX6yOFk4OTV2NB?=
PANC-1  NWjmcWhDTnWwY4Tpc44hSXO|YYm= Mk\LNVAhdk1? MV:3NkBp M3LqU4lv[3KnYYPld{Bo\W2laYThZolv\SC|ZX7zbZRqfmm2eR?= NF;1ZXQzPDl5MUW0OC=>

... Click to View More Cell Line Experimental Data

In vivo試験 In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day. [1] Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models. [2]
臨床試験 INK 128 is currently in Phase I clinical trials in patients with relapsed or refractory multiple myeloma or waldenstrom macroglobulinemia.
特集

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download INK 128 (MLN0128) SDF
分子量 309.33
化学式

C15H15N7O

CAS No. 1224844-38-5
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 62 mg/mL (200.43 mM)
エタノール 2 mg/mL (6.46 mM)
<1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

文献中の引用 (7)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

最近チェックしたアイテム

Tags: INK 128 (MLN0128)を買う | INK 128 (MLN0128)供給者 | INK 128 (MLN0128)を購入する | INK 128 (MLN0128)費用 | INK 128 (MLN0128)生産者 | オーダーINK 128 (MLN0128) | INK 128 (MLN0128)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ